P-gp、MMP-2、C-erbB-2 在乳腺癌原发灶和转移淋巴结中的表达对比研究

目的:探讨乳腺癌侵袭转移和多药耐药之间的关系,为治疗方案的个体化提供依据。方法:采用免疫组化方法检测46例乳腺浸润性导管癌患者乳腺原发灶及相应腋淋巴结转移灶中P-gp、MMP-2、c-erbB-2的表达,结合临床表现、病理学指标,分析其相关性。结果:46例原发灶P-gp阳性表达35例(76.1%),MMP-2阳性表达25例(54.3%),c-erbB-2高表达18例(39.1%);相应腋淋巴结转移灶P-gp阳性表达28例(60.9%),MMP-2阳性表达16例(34.8%),c-erbB-2高表达16例(34.8%);P-gp、MMP-2蛋白表达水平与肿块大小、淋巴结转移数目均呈正相关(P<0.05),c-erbB-2蛋白表达水平与腋窝淋巴结转移数量呈正相关,与ER、PR表达呈负相关,P-gp阳性表达与MMP-2和c-erbB-2的表达呈正相关(P<0.05)。结论:肿瘤原发灶与转移灶存在异质性,P-gp、MMP-2、c-erbB-2的表达与乳腺癌的多药耐药和侵袭转移有关,检测上述基因在原发灶与转移灶的表达,为乳腺癌选择个体化的化疗、内分泌治疗及分子靶向治疗提供了分子生物学依据。

Expression and clinical significance of P-gp, MMP-2 and c-erbB-2 in infiltrating ductal breast cancer and metastatic axillary lymph nodes

Objective: To observe the expression of P-gp,MMP-2 and c-erbB-2 in primary tumor and their metastatic axillary lymph nodes and study the relationship with clinicopathology characteristics and also the correlation between P-gp,MMP-2 and c-erbB-2.Methods: Immunohistochemical technique was performed to detect the expression of P-gp,MMP-2 and c-erbB-2 in 46 cases of infiltrating ductal breast cancer with primary tumor and their metastatic axillary lymph nodes without undergoing neo-adjuvent therapy.Their clinic...